AMGN Amgen Accounting Capitalization

Risks for Amgen Inc. (AMGN) are centered on the loss of exclusivity for legacy formulas and government price controls, which are offset by a strong pipeline. Amidst fierce competition from low-cost generics, the company is betting on the acquisition of innovative startups, and the indicator stands at 11.59. The stock's price history complements data regarding the ownership of high-tech plants across various regions, ensuring the stability of biologic production.

AMGN Amgen Inc Book Capitalization (07/04/2022 - 10/28/2026)

Metric breakdowns and analytics for Amgen (AMGN)

- price and consensus price forecast:

Price Rate Chart Amgen Inc|AMGN - Price Target Chart

- market capitalization data:

Market Capitalization Amgen Corp|AMGN - Total Company Value

- book capitalization data:

Share Book Value Amgen|AMGN - Book Capitalization|Market Value to Book Value amgen.com|AMGN - Company Total Assets

- debt and liquidity data:

Total Debt to Capital Amgen Inc.|AMGN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Amgen Corp|AMGN - Company Debts|Debt to Book Value Amgen Corp

Fundamental valuation:AMGN - Amgen Inc

Book value capitalization measures the total value of Amgen Inc. (AMGN) net assets minus all debt obligations. This indicator allows for an assessment of the business's real value, stripped of leveraged capital. The current book value confirms the financial stability of the biopharmaceutical behemoth. Stable demand for life-saving drugs ensures a constant cash flow, which minimizes volatility risks and guarantees capital protection during economic downturns.

Competitor analysis for Amgen Inc.